|
Daehan Nupharm Breaks Ground on New GMP Plant Aligned with International Guidelines "A Key Driver for Future Growth"
2024.05.18
|
|---|
|
Daehan Nupharm held a groundbreaking and safety prayer ceremony on October 17 for the construction of a new GMP production facility at its Hyangnam plant site, marking a major step toward strengthening its global manufacturing competitiveness. The new facility will involve an investment of KRW 42.9 billion and will cover a total floor area of 15,123 m², consisting of one basement level and five above-ground floors. Construction is scheduled to take 15 months, followed by a validation period, with full-scale production beginning in 2027. This initiative is part of the company’s long-term strategy to build future growth engines. In 2021, Daehan Nupharm opened its Industry-Academia-Research Center to enhance R&D capabilities. Since 2022, the company has strategically advanced the “Hyangnam Project 1·2·3.”
The new plant will be equipped with state-of-the-art injection and solid dosage production lines, as well as storage facilities.
Korea has strengthened its pharmaceutical quality and export competitiveness since joining the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2014. In December 2023, the Ministry of Food and Drug Safety (MFDS) revised its GMP regulations to mandate contamination control strategies for sterile products. The construction of Daehan Nupharm’s new plant fully complies with these global regulatory standards, positioning the company to further enhance its export capabilities.
As the largest investment in the company’s history, this new facility has been carefully planned from the design stage to optimize operational efficiency. Beyond increasing production capacity, Daehan Nupharm aims to secure a stable supply of high-quality pharmaceuticals, expand global exports, and advance R&D initiatives—paving the way to become a leading global pharmaceutical and biotech company. |


Home

